US EditionFDA Approves Merck RSV Shot for Infants — Despite High Rates of Serious Reactions
Summary by Natural Blaze
1 Articles
1 Articles
FDA Approves Merck RSV Shot for Infants — Despite High Rates of Serious Reactions
Story at-a-glance Merck’s respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly... Continue reading...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
